<h2>Ypsomed Holding 最新财报对股东的重要性</h2>
<p>Ypsomed Holding (SWX:YPSN) 刚刚发布了截至 2026 年 3 月 31 日的全年业绩，报告净收入为 2.2193 亿瑞士法郎，来自持续经营的基本每股收益为 16.31 瑞士法郎。</p>
<p>这些数字与去年同期的净收入 8750 万瑞士法郎和基本每股收益 6.41 瑞士法郎相比，突显了任何关注该股票近期走势的投资者对收益的关注。</p>
<p>请查看我们对 Ypsomed Holding 的最新分析。</p>
<p>最新业绩发布后，股票经历了急剧上涨，1 个月的股价回报为 20.82%，3 个月的股价回报为 25.23%，尽管 1 年的总股东回报下降了 11.45%，而 5 年的总股东回报上升了 128.50%。这表明短期动能在仍然强劲的长期记录下有所增强。</p>
<p>如果这些收益让你重新考虑你的医疗保健投资，可以使用我们的筛选器扫描 126 只医疗保健人工智能股票，寻找其他潜在机会。</p>
<p>每股收益为 16.31 瑞士法郎，价值评分为 5，内在折扣为 41.80%，且股价仍低于平均分析师目标价，你应该将 Ypsomed 视为被低估，还是市场已经在定价未来的增长？</p>
<h2>最受欢迎的叙述：低估 12.3%</h2>
<p>Ypsomed Holding 最受关注的叙述将公允价值定为 387.82 瑞士法郎，而最后收盘价为 340 瑞士法郎，框架内的最新收益形成了估值差距。</p>
<blockquote>
<p><em>Ypsomed 转向 B2B 模式和本地制造可能简化运营，提高专注度，并降低地缘政治风险，这可能提升利润率和收益。公司扩大的生产能力，包括对新装配线的投资和工具车间的翻倍，令 Ypsomed 能够满足未来需求，特别是在快速增长的自动注射器等细分市场，可能推动收入增长。</em></p>
</blockquote>
<p><em>阅读完整叙述。</em></p>
<p>想知道 387.82 瑞士法郎的公允价值中包含了什么吗？收入增长、利润率提升和利润倍数都朝不同方向拉动。</p>
<p><strong>结果：公允价值为 387.82 瑞士法郎（被低估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，这取决于 Ypsomed 能否顺利执行其扩张和剥离计划，因为在大型产能项目或 GLP 1 合作伙伴关系中出现任何问题都可能迅速挑战这一叙述。</p>
<p>了解 Ypsomed Holding 叙述的关键风险。</p>
<h2>下一步</h2>
<p>在风险和回报并存的情况下，这些结果是否让你感到信服或谨慎，你希望多快明确你的观点？为了更详细地权衡上行潜力与担忧，仔细查看 4 个关键回报和 1 个重要警示信号。</p>
<h2>寻找更多投资想法？</h2>
<p>如果你在这里停止研究，可能会错过更符合你目标的股票。继续建立你的候选名单，让数字来进行筛选。</p>
<ul>
<li>通过扫描包含 531 只高质量未被发现的股票的筛选器，提前发现潜在的便宜货，这些股票结合了稳健的基本面和较低的市场关注度。</li>
<li>通过查看稳健资产负债表和基本面股票筛选器（390 个结果），加强你的核心持股，这些公司专注于韧性和财务纪律。</li>
<li>通过查看 480 只旨在提供更高收益并强调耐久性的股息堡垒，瞄准以收入为重点的机会。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

<p>Ypsomed Holding (SWX:YPSN) 报告截至 2026 年 3 月 31 日的净收入为 2.2193 亿瑞士法郎，每股收益为 16.31 瑞士法郎，较前一年的 8750 万瑞士法郎和 6.41 瑞士法郎有显著增长。尽管过去一年总股东回报下降了 11.45%，但该股票在过去一个月内的回报率达到了 20.82%。分析师认为该股票被低估，公允价值为 387.82 瑞士法郎，显示出未来增长的潜力，前提是成功执行扩张计划</p>

<h2>Why Ypsomed Holding’s latest earnings matter for shareholders</h2>
<div class="lb-trans"><h2>Ypsomed Holding 最新财报对股东的重要性</h2>
</div><p>Ypsomed Holding (SWX:YPSN) just released full year results to March 31, 2026, reporting net income of CHF 221.93 million and basic earnings per share of CHF 16.31 from continuing operations.</p>
<div class="lb-trans"><p>Ypsomed Holding (SWX:YPSN) 刚刚发布了截至 2026 年 3 月 31 日的全年业绩，报告净收入为 2.2193 亿瑞士法郎，来自持续经营的基本每股收益为 16.31 瑞士法郎。</p>
</div><p>These figures compare with net income of CHF 87.5 million and basic earnings per share of CHF 6.41 a year earlier, putting earnings firmly in focus for anyone tracking the stock’s recent move.</p>
<div class="lb-trans"><p>这些数字与去年同期的净收入 8750 万瑞士法郎和基本每股收益 6.41 瑞士法郎相比，突显了任何关注该股票近期走势的投资者对收益的关注。</p>
</div><p>See our latest analysis for Ypsomed Holding.</p>
<div class="lb-trans"><p>请查看我们对 Ypsomed Holding 的最新分析。</p>
</div><p>The latest results arrive after a sharp run in the stock, with a 1 month share price return of 20.82% and 3 month share price return of 25.23%, even though the 1 year total shareholder return is down 11.45% while the 5 year total shareholder return is up 128.50%. This suggests short term momentum has picked up against a still strong longer term record.</p>
<div class="lb-trans"><p>最新业绩发布后，股票经历了急剧上涨，1 个月的股价回报为 20.82%，3 个月的股价回报为 25.23%，尽管 1 年的总股东回报下降了 11.45%，而 5 年的总股东回报上升了 128.50%。这表明短期动能在仍然强劲的长期记录下有所增强。</p>
</div><p>If these earnings have you rethinking your healthcare exposure, it can be useful to scan other potential opportunities in the sector using our screener for 126 healthcare AI stocks.</p>
<div class="lb-trans"><p>如果这些收益让你重新考虑你的医疗保健投资，可以使用我们的筛选器扫描 126 只医疗保健人工智能股票，寻找其他潜在机会。</p>
</div><p>With earnings per share at CHF 16.31, a value score of 5, an indicated intrinsic discount of 41.80% and a share price still below the average analyst target, should you view Ypsomed as undervalued, or is the market already pricing in future growth?</p>
<div class="lb-trans"><p>每股收益为 16.31 瑞士法郎，价值评分为 5，内在折扣为 41.80%，且股价仍低于平均分析师目标价，你应该将 Ypsomed 视为被低估，还是市场已经在定价未来的增长？</p>
</div><h2>Most Popular Narrative: 12.3% Undervalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：低估 12.3%</h2>
</div><p>Ypsomed Holding's most followed narrative puts fair value at CHF 387.82 versus a last close of CHF 340, framing the latest earnings in a valuation gap.</p>
<div class="lb-trans"><p>Ypsomed Holding 最受关注的叙述将公允价值定为 387.82 瑞士法郎，而最后收盘价为 340 瑞士法郎，框架内的最新收益形成了估值差距。</p>
</div><blockquote>
<p><em>Ypsomed's shift to a B2B model and local manufacturing may streamline operations, improve focus, and reduce geopolitical risks, which could enhance margins and earnings. The company's expanded manufacturing capacity, including investment in new assembly lines and doubling its tool shop, positions Ypsomed to meet future demand, especially in fast-growing segments like auto-injectors, potentially boosting revenues.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>Ypsomed 转向 B2B 模式和本地制造可能简化运营，提高专注度，并降低地缘政治风险，这可能提升利润率和收益。公司扩大的生产能力，包括对新装配线的投资和工具车间的翻倍，令 Ypsomed 能够满足未来需求，特别是在快速增长的自动注射器等细分市场，可能推动收入增长。</em></p>
</blockquote>
</div><p><em>Read the complete narrative.</em></p>
<div class="lb-trans"><p><em>阅读完整叙述。</em></p>
</div><p>Want to see what is baked into that fair value of CHF 387.82? Revenue pacing, margin gains and the profit multiple all pull in different directions.</p>
<div class="lb-trans"><p>想知道 387.82 瑞士法郎的公允价值中包含了什么吗？收入增长、利润率提升和利润倍数都朝不同方向拉动。</p>
</div><p><strong>Result: Fair Value of CHF 387.82 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 387.82 瑞士法郎（被低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, this depends on Ypsomed executing its expansion and divestment plans cleanly, since any hiccups in large capacity projects or GLP 1 partnerships could quickly challenge that narrative.</p>
<div class="lb-trans"><p>然而，这取决于 Ypsomed 能否顺利执行其扩张和剥离计划，因为在大型产能项目或 GLP 1 合作伙伴关系中出现任何问题都可能迅速挑战这一叙述。</p>
</div><p>Find out about the key risks to this Ypsomed Holding narrative.</p>
<div class="lb-trans"><p>了解 Ypsomed Holding 叙述的关键风险。</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><p>With both risks and rewards on the table, do these results leave you convinced or cautious, and how quickly do you want to firm up your view? To weigh the upside against the concerns in more detail, take a closer look at the 4 key rewards and 1 important warning sign.</p>
<div class="lb-trans"><p>在风险和回报并存的情况下，这些结果是否让你感到信服或谨慎，你希望多快明确你的观点？为了更详细地权衡上行潜力与担忧，仔细查看 4 个关键回报和 1 个重要警示信号。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>If you stop your research here, you could miss stocks that better fit your goals. Keep building your shortlist and let the numbers do the filtering.</p>
<div class="lb-trans"><p>如果你在这里停止研究，可能会错过更符合你目标的股票。继续建立你的候选名单，让数字来进行筛选。</p>
</div><ul>
<li>Spot potential bargains early by scanning screener containing 531 high quality undiscovered gems that combine solid fundamentals with lower market attention.</li>
<li>Strengthen your core holdings by reviewing companies in the solid balance sheet and fundamentals stocks screener (390 results) that focus on resilience and financial discipline.</li>
<li>Target income-focused opportunities by checking out 480 dividend fortresses that aim for higher yields with an emphasis on durability.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过扫描包含 531 只高质量未被发现的股票的筛选器，提前发现潜在的便宜货，这些股票结合了稳健的基本面和较低的市场关注度。</li>
<li>通过查看稳健资产负债表和基本面股票筛选器（390 个结果），加强你的核心持股，这些公司专注于韧性和财务纪律。</li>
<li>通过查看 480 只旨在提供更高收益并强调耐久性的股息堡垒，瞄准以收入为重点的机会。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

分析 Ypsomed Holding（SWX:YPSN）在 2026 年全年强劲收益结果后的估值